Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.

Sansone, Emanuele; Tiraboschi, Mara Maria; Sala, Emma; Albini, E; Lombardo, Mónica E.; Castelli, Francesco; Palma, Giuseppe De

doi:10.1016/j.jinf.2021.04.038

Cited by 23 publications

(36 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 16 studies met the inclusion criteria [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] and were included in the final review (Table 1). All of these studies were nonrandomized: 8 were retrospective cohort studies, 18,19,[21][22][23]26,30,33 6 were prospective cohort studies, 20,25,28,29,31,32 and 2 were case-control studies. 24,27 All of the studies evaluated the Pfizer/BioNTech mRNA COVID-19 vaccine, [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…All of these studies were nonrandomized: 8 were retrospective cohort studies, 18,19,[21][22][23]26,30,33 6 were prospective cohort studies, 20,25,28,29,31,32 and 2 were case-control studies. 24,27 All of the studies evaluated the Pfizer/BioNTech mRNA COVID-19 vaccine, [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] 2 studies also analyzed the Moderna mRNA COVID-19 vaccine, 27,31 and another study also analyzed the AstraZeneca COVID-19 vaccine 25 (but this study was not considered in the vaccine effectiveness analysis). No study evaluated the vaccine effectiveness for the Johnson & Johnson/ Janssen vaccine.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Nearly all HCWs (99.9%) were vaccinated with the Pfizer/BioNTech COVID-19 mRNA vaccine. [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Most of the studies included in our review were conducted in the United States (6 studies) 21,27,28,[30][31][32] ; 3 studies were performed in Italy 20,22,29 ; 3 were performed in the United Kingdom 23,25,26 ; 2 studies were performed in Israel 18,19 ; 1 was conducted in Spain 24 ; and 1 was conducted in Ireland. 32 All studies were performed between December 2020 and April 2021.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…32 All studies were performed between December 2020 and April 2021. [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Overall, we included 195,801 HCWs in the qualitative analysis. Moreover, 6 studies evaluated vaccine effectiveness >7 days after the second dose, 19,20,22,25,27,29 3 studies evaluated vaccine effectiveness >14 days after the second dose, 21,30,32 1 study evaluated vaccine effectiveness after HCWs received the second dose on day 21 or day 22 after the first dose, 18 and the other 6 studies did not report the time the vaccine was considered effective.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Marra

Kobayashi

Suzuki

et al. 2021

ASHE

View full text Add to dashboard Cite

Objective: Healthcare workers (HCWs) are at risk of COVID-19 due to high levels of SARS-CoV-2 exposure. Thus, effective vaccines are needed. We performed a systematic literature review and meta-analysis on COVID-19 short-term vaccine effectiveness among HCWs. Methods: We searched PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 2019 to June 11, 2021, for studies evaluating vaccine effectiveness against symptomatic COVID-19 among HCWs. To meta-analyze the extracted data, we calculated the pooled diagnostic odds ratio (DOR) for COVID-19 between vaccinated and unvaccinated HCWs. Vaccine effectiveness was estimated as 100% × (1 − DOR). We also performed a stratified analysis for vaccine effectiveness by vaccination status: 1 dose and 2 doses of the vaccine. Results: We included 13 studies, including 173,742 HCWs evaluated for vaccine effectiveness in the meta-analysis. The vast majority (99.9%) of HCWs were vaccinated with the Pfizer/BioNTech COVID-19 mRNA vaccine. The pooled DOR for symptomatic COVID-19 among vaccinated HCWs was 0.072 (95% confidence interval [CI], 0.028–0.184) with an estimated vaccine effectiveness of 92.8% (95% CI, 81.6%–97.2%). In stratified analyses, the estimated vaccine effectiveness against symptomatic COVID-19 among HCWs who had received 1 dose of vaccine was 82.1% (95% CI, 46.1%–94.1%) and the vaccine effectiveness among HCWs who had received 2 doses was 93.5% (95% CI, 82.5%–97.6%). Conclusions: The COVID-19 mRNA vaccines are highly effective against symptomatic COVID-19, even with 1 dose. More observational studies are needed to evaluate the vaccine effectiveness of other COVID-19 vaccines, COVID-19 breakthrough after vaccination, and vaccine efficacy against new variants.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Marra

Kobayashi

Suzuki

et al. 2021

ASHE

View full text Add to dashboard Cite

show abstract

“…Sasone et al analyzed the evaluated the effectiveness of BNT162b2 in Brescia country, where the B.1.1.7 variant was highly prevalent (70–97%). They found the vaccine was effective in reducing infection rate among vaccinated HCWs ( 176 ). The estimated effectiveness of the BNT162b2 against infection with B.1.1.7 variant and B.1.351 variant was 89.5 and 75%, respectively.…”

Section: Sars-cov-2 Vaccinementioning

confidence: 99%

Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19)

Kang

Peng

et al. 2021

Front. Med.

View full text Add to dashboard Cite

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to public concern worldwide. Although a variety of hypotheses about the hosts of SARS-CoV-2 have been proposed, an exact conclusion has not yet been reached. Initial clinical manifestations associated with COVID-19 are similar to those of other acute respiratory infections, leading to misdiagnoses and resulting in the outbreak at the early stage. SARS-CoV-2 is predominantly spread by droplet transmission and close contact; the possibilities of fecal–oral, vertical, and aerosol transmission have not yet been fully confirmed or rejected. Besides, COVID-19 cases have been reported within communities, households, and nosocomial settings through contact with confirmed COVID-19 patients or asymptomatic individuals. Environmental contamination is also a major driver for the COVID-19 pandemic. Considering the absence of specific treatment for COVID-19, it is urgent to decrease the risk of transmission and take preventive measures to control the spread of the virus. In this review, we summarize the latest available data on the potential hosts, entry receptors, clinical features, and risk factors of COVID-19 and transmission routes of SARS-CoV-2, and we present the data about development of vaccines.

show abstract

SARS-CoV-2 infection after vaccination in Italian health care workers: a case report

Cafiero

Palmirotta

Micera

et al. 2022

Natl. Acad. Sci. Lett.

View full text Add to dashboard Cite

Following the approval of COVID-19 vaccination program by EMA and national authorities, an immunization campaign started in Italy with BNT162b2mRNA vaccine, initially focused on healthcare workers. The active immunization was monitored by systemic antibody titration and continuous surveillance was guaranteed by antigenic/molecular tests on swabs. Cases of infection have been recently observed in vaccinated healthcare workers. Herein we describe an outbreak of infection occurring in five physicians out of 656 healthcare workers belonging to a private hospital, referring mild symptoms of COVID-19. Healthcare workers underwent complete vaccination and screening for antibody titration. Five out of 656 healthcare workers were tested positive for SARS-CoV-2 in nasopharyngeal swabs and referred mild COVID-19 symptoms. Molecular analyses were carried out to identify possible variants of Spike protein. Their genotyping performed on RNA extracts highlighted the presence of del69/70, N501Y, A570D, and 1841A > G (D614G) sequence variants, all indicative of VOC 202012/01-lineage B.1.1.7, suggesting a common source of infection. These cases might represent a serious emergency because outbreaks can compromise frail patients with important concomitant diseases.

show abstract

Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.

Cited by 23 publications

References 6 publications

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19)

SARS-CoV-2 infection after vaccination in Italian health care workers: a case report

Contact Info

Product

Resources

About